Marker Therapeutics, Inc.

Monthly Archives: March 2014

TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart™

...New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient’s immune system, a critical aspect of an effective vaccine.
Read More

TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer

SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.
Read More

TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference

Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
Read More

TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer

Results Meet Management’s Highest Expectations SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes.
Read More